-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
-
Indian pharma fuels Africa's 'zombie drug' and opioid crisis
-
After months of blackout, Iran gives internet to select few
-
Wood urges New Zealand to 'create some history' at World Cup
-
In Washington, the fight to preserve Black cemeteries
-
US children's book author sentenced to life after poisoning husband
-
Emotional Vin Diesel leads 'Fast and Furious' tribute in Cannes
-
AVI Urges the Dismissal of Two Directors at Wacom
-
PLAS-LABS Simplifies Scientific Validation With Automated Citation Tracking Powered by Bioz
-
Battery X Metals Achieves Milestone with Delivery of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Machine Featuring Design Enhancements, Advancing Strategic Commercialization Initiatives
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 14
-
Akkodis Recognized in HFS Horizons 2026 Report for Enterprise Ready Agentic AI Services
-
Lexus Of Oakville Recognized for Redefining the Luxury Dealership Experience With 2026 Consumer Choice Award
-
US renews offer of $100 mn to Cuba if it cooperates
-
City still 'alive' but need Arsenal slip: Guardiola
-
Man City ease past Palace to keep pressure on Arsenal
-
Alaves end champions Barca's bid for 100-point record
-
US jury begins deliberations on 737 MAX victim suit against Boeing
-
PSG clinch fifth straight Ligue 1 title
-
Inter Milan win Italian Cup to secure domestic double
-
Man City see off Palace to keep pressure on Arsenal
-
Trump and Xi set for high-stakes talks in Beijing
-
S&P 500, Nasdaq end at records as oil prices retreat
-
Iran holds World Cup send-off for national football team
Science of sleep: Why a good night's rest gets harder with age
It's well known that getting a good night's sleep becomes more difficult as we age, but the underlying biology for why this happens has remained poorly understood.
A team of US scientists has now identified how the brain circuitry involved in regulating sleepfulness and wakefulness degrades over time in mice, which they say paves the way for better medicines in humans.
"More than half of people 65 and older complain about the quality of sleep," Stanford University professor Luis de Lecea, who co-authored a study about the finding published Thursday in Science, told AFP.
Research has shown that sleep deprivation is linked to an increased risk of multiple poor health outcomes, from hypertension to heart attacks, diabetes, depression and a build up of brain plaque linked to Alzheimer's.
Insomnia is often treated with a class of drugs known as hypnotics, which include Ambien, but these don't work very well in the elderly population.
For the new study, de Lecea and colleagues decided to investigate hypocretins, key brain chemicals that are generated only by a small cluster of neurons in the brain's hypothalamus, a region located between the eyes and ears.
Of the billions of neurons in the brain, only around 50,000 produce hypocretins.
In 1998, de Lecea and other scientists discovered that hypocretins transmit signals that play a vital role in stabilizing wakefulness.
Since many species experience fragmented sleep as they grow old, it's hypothesized that the same mechanisms are at play across mammals, and prior research had shown degradation of hypocretins leads to narcolepsy in humans, dogs and mice.
The team selected young (three to five months) and old mice (18 to 22 months) and used light carried by fibers to stimulate specific neurons. They recorded the results using imaging techniques.
What they found was that the older mice had lost approximately 38 percent of hypocretins compared to younger mice.
They also discovered that the hypocretins that remained in the older mice were more excitable and easily triggered, making the animals more prone to waking up.
This might be because of the deterioration over time of "potassium channels," which are biological on-off switches critical to the functions of many types of cells.
"The neurons tend to be more active and fire more, and if they fire more, you wake up more frequently," said de Lecea.
Identifying the specific pathway responsible for sleep loss could lead to better drugs, argued Laura Jacobson and Daniel Hoyer, of Australia's Florey Institute of Neuroscience and Mental Health, in a related commentary article.
Current treatments, such as hypnotics, "can induce cognitive complaints and falls," and medicines that target the specific channel might work better, they said.
These will need to be tested in clinical trials -- but an existing drug known as retigabine, which is currently used to treat epilepsy and which targets a similar pathway -- could be promising, said de Lecea.
K.Hill--AT